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Summary
Trilostane therapy, the treatment of choice for pitui-
tary-dependent hyperadrenocorticism (HAC) in dogs, 
is monitored by assessing resolution of clinical signs and 
measuring adrenocortical reserve capacity with an 
ACTH-stimulation test. The aim of this prospective 
study was to evaluate agreement between clinical signs 
reported by owners and cortisol or ACTH concentra-
tions before and during trilostane therapy (starting dose 
1–2 mg/kg once daily). A questionnaire on signs of HAC 
was used and a clinical score calculated as the sum of 
the 9 questions. Eighteen questionnaires at diagnosis 
and 97 during therapy were filled out by owners of 
32 dogs. An ACTH-stimulation test was performed at 
each reevaluation. There were weak correlations between 
abdominal girth, appetite or weight gain and cortisol 
concentrations during therapy. However, the clinical 
score did not correlate with cortisol or cACTH values. 
In 50% of dogs, trilostane application had to be changed 
from once daily to twice daily during the study. Clinical 
signs reported by owners matched poorly with cortisol 
or cACTH concentrations at any time point. If low-dose 
trilostane is used, treatment frequency often has to be 
increased.
Keywords: questionnaire, medical therapy, ACTH-stimula-
tion test, cortisol, canine
Fehlender Zusammenhang zwischen 
klinischen Symptomen und Labor-
werten von Hunden mit Hyperadre-
nokortizismus vor und während der 
Trilostan-Behandlung
Die Behandlung mit Trilostan, dem Medikament der 
Wahl zur Therapie eines hypophysen-abhängigen Hype-
radrenokortizismus (HAK) beim Hund, wird anhand des 
Verschwindens der klinischen Symptome und des Resul-
tates des ACTH-Stimulationstestes beurteilt. Das Ziel 
dieser prospektiven Studie war die Übereinstimmung der 
klinischen Symptome (beurteilt durch Besitzer) mit den 
Kortisol- und endogenen ACTH-Konzentrationen vor 
und während der Trilostantherapie (Startdosis 1–2 mg/kg 
1× täglich) zu untersuchen. Ein Fragebogen mit 9 Fragen 
zur Klinik des HAK wurde verwendet und ein klinischer 
Gesamtscore als Summe berechnet. Achtzehn Fragebö-
gen zum Zeitpunkt der Diagnosestellung und 97 unter 
Therapie wurden von Besitzern von 32 Hunden ausge-
füllt. Ein ACTH-Stimulationstest wurde zu jedem Kon-
trollzeitpunkt durchgeführt. Es fanden sich schwache 
Korrelationen von Bauchumfang, Appetit und Gewichts-
zunahme mit den Kortisolwerten während der Therapie. 
Der klinische Gesamtscore korrelierte aber nicht mit den 
Kortisol- oder ACTH-Konzentrationen. Bei 50% der 
Hunde musste die Trilostangabe während der Studie von 
ein- auf zweimal täglich umgestellt werden. Klinische 
Symptome beurteilt durch Besitzer zeigen eine schlech-
te Übereinstimmung mit Kortisol- und ACTH-Konzen-
trationen während der Trilostantherapie. Wird Trilostan 
tief-dosiert eingesetzt, muss die Applikationshäufigkeit 
oft erhöht werden. 
Schlüsselwörter: Fragebogen, medikamentelle Therapie, 
ACTH-Stimulationstest, Kortiosl, Hund
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Introduction
Trilostane is the treatment of choice for dogs with pitu-
itary-dependent hyperadrenocorticism (HAC). Trilos-
tane is a competitive inhibitor of the 3β-hydroxysteroid 
dehydrogenase enzyme system and interferes with syn-
thesis of glucocorticoids at the level of the adrenal 
glands. Trilostane has been shown to reduce the circu-
lating concentrations of cortisol leading to substantial 
improvement of clinical signs in 70 to 96% of cases 
(Ruckstuhl et al., 2002; Braddock et al., 2003; Neiger et 
al., 2003). Since its first use in veterinary medicine, the 
recommended daily dose has been adjusted several 
times. Especially with the introduction of the veterinary 
product in the year 2002 in Europe, endocrinologists 
experienced a need to significantly reduce the daily 
dose from the originally prescribed > 4–10 mg/kg to 
1–2 mg/kg per day. 
It is well known that the maximum effect of trilostane 
on glucocorticoid production is reached 2–4 hours after 
application and that trilostane does not normalize cor-
tisol concentrations in dogs with HAC for 24 hours 
(Lehnert, 2007). Based on this, some authors postulate 
that using trilostane twice daily will increase the number 
of dogs with a good clinical response (Arenas et al., 
2013). However, there is still no consensus on the opti-
mal frequency of administration. 
Treatment response is monitored by assessing improve-
ment or resolution of clinical signs and by measuring the 
adrenocortical reserve capacity with an ACTH-stimula-
tion test (Ruckstuhl et al., 2002; Neiger et al., 2003). 
However, this test is time consuming and expensive. 
Moreover, concerns have been raised that synthetic 
ACTH, if applied in excessive amounts, could have del-
eterious effects on adrenal glands (Burkhardt et al., 2011). 
Therefore a monitoring system without the need for 
ACTH-stimulation, but with which both over- and un-
derdosed animals could be safely and timely identified, 
would be preferable. The assessment of clinical signs as 
an alternative to monitoring trilostane treatment has 
been investigated by two groups (Wehner et al., 2013; 
Ramsey et al., 2015). Results, however, are only available 
as abstracts and are somewhat contradictory. While in 
the first study, no correlation between clinical signs and 
ACTH-stimulation test results during trilostane therapy 
were observed (Wehner et al., 2013), in the second, a 
weak correlation between clinical signs and cortisol con-
centrations could be shown (Ramsey et al., 2015).
Both research groups included dogs solely during ther-
apy but not at the time of diagnosis (Wehner et al., 2013; 
Ramsey et al., 2015). The latter, however, would be an 
interesting time point to evaluate a possible correlation 
between clinical signs and cortisol or ACTH concentra-
tions, as one could hypothesize that clinical signs 
reported by owners would be more severe in dogs 
with higher cortisol or ACTH concentrations. Still, no 
studies have addressed this hypothesis. 
Therefore, the objectives of the study were multiple. 
First, we wanted to evaluate the agreement between clin-
ical signs reported by the owners and cortisol and 
cACTH concentrations at the time of diagnosis as well 
as during trilostane therapy. Second, we wanted to assess 
the number of dogs in which the treatment regimen had 
to be changed from once to twice daily during therapy. 
Animals, Material and Methods
Animals
Thirty-two client-owned dogs with HAC were included 
in the study. Age ranged from 6 to 14 years (median, 
11 years) and bodyweight from 2.1 to 39.7 kg (median, 
14.5 kg). There were 16 females (13 spayed) and 16 males 
(11 castrated). The most frequently represented breeds 
were mixed breed (5), Dachshund (n=2) and Dandie 
Dinmont Terrier (2). There was 1 Australian Cattle Dog, 
Basset Hound, Bedlington Terrier, Bichon Frisé, Border 
Collie, Boxer, Cairn Terrier, Dalmatian, Doberman, Flat 
Coated Retriever, Eurasier, French Bulldog, Labrador 
Retriever, Maltese, Nova Scotia Duck Tolling Retriever, 
Papillon, Parson Jack Russell Terrier, Pekingese, Pomera-
nian, Tibetan Terrier, Toy Poodle, West Highland White 
Terrier and Yorkshire Terrier. Twenty-nine dogs were di-
agnosed with pituitary-dependent hyperadrenocorticism 
(PDH) and 2 with adrenal-dependent hyperadrenocorti-
cism (ADH). In 1 dog differentiation between PDH and 
ADH was not possible. 
Study design
The prospective study was conducted between Decem-
ber 2010 and October 2014 at our facility. 
Dogs suspected of having hyperadrenocorticism under-
went a thorough clinical examination. Blood and urine 
samples were collected for a CBC, biochemical profile, 
urinalysis and urine culture. Further work-up included 
an ACTH-stimulation test, a low-dose dexamethasone 
suppression test (LDDS) and/or measurement of the 
urinary corticoid:creatinine ratio (UCCR) and ultra-
sonographic examination of the adrenal glands. PDH 
or ADH was diagnosed on the basis of the dog’s con-
centration of endogenous ACTH (cACTH) and/or the 
ultrasonographic appearance of the adrenal glands. 
Dogs were included in the study when consistent clinical 
and laboratory findings for HAC were present, the LDDS 
and/or the ACTH-stimulation test and/or the urinary 
UCCR were positive, the dog had not received other 
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treatments (radiation treatment or mitotane) and at least 
one owner questionnaire had been filled out. Dogs with 
concurrent diseases (e.g. diabetes mellitus, chronic renal 
disease) were excluded from the study. Informed consent 
was obtained from the owners of all dogs. Their use 
complied with the guidelines and directives established 
by the Animal Welfare Act of Switzerland.
Disease-specific questionnaires 
The disease-specific questionnaire included 9 questions 
about polyuria, polydipsia, appetite, panting, amount 
of sleep, body weight increase, abdominal girth, activi-
ty level, and general attitude. For each question the 
owner could rate the severity of a symptom between 
1–10 (5=normal, 10=severe). Symptom scores were re-
corded and a total clinical score calculated by adding 
the scores for each clinical symptom. A total clinical 
score of 45 represented a well-controlled  dog. Total 
clinical scores > 45–90 represented dogs with mild (46) 
to severe (90) clinical signs of HAC. The clinical scores 
derived from the owner questionnaire were then cate-
gorized into one of 3 groups: excessive (< 45), adequate 
(45–50) or inadequate (> 50) control of HAC.
Diagnostic testing and hormone analysis 
The ACTH-stimulation tests were performed by collect-
ing blood samples for determination of serum cortisol 
before and 1 hour after intravenous or intramuscular 
injection of 5 ug/kg of synthetic ACTH (Synacthen®, 
Novartis Pharma Schweiz AG, Bern, Switzerland). A 
cortisol concentration of > 17 ug/dl was considered con-
sistent with HAC. The LDDS test was performed as 
described previously (Braun et al., 2013). A cortisol con-
centration of ≥ 1.0 ug/dl at 8 hours or of ≥ 1 ug/dl at 
4 hours and < 1 ug/dl at 8 hours (inverse result, Mueller 
et al., 2006) after dexamethasone administration was 
considered consistent with HAC. Serum cortisol con-
centrations were determined by use of chemilumines-
cence assays (DPC Immulite® 1000, Siemens AG, 
Zurich, Switzerland). Urinary corticoid concentrations 
were measured by use of a radioimmunoassay (RIA 
Beckmann, Unilabs Dr. Weber, St. Gallen, Switzerland). 
A UCCR of > 10 × 10-6 was considered abnormal. En-
dogenous ACTH was determined before ACTH-stimu-
lation by collecting blood into chilled EDTA-coated 
tubes placed on ice. After centrifugation at 4 °C, plasma 
was stored at –80 °C until assayed. Measurement was 
performed by a chemiluminescence assay (DPC Immu-
lite® 1000, Siemens AG, Zurich, Switzerland). 
Trilostane therapy
The initial dose of trilostane was 1–2 mg/kg bodyweight 
orally q24h. Efficacy of trilostane treatment was assessed 
at each re-evaluation based on the clinical signs docu-
mented by the attending clinician and the results of 
ACTH-stimulation testing. ACTH-stimulation tests 
were performed at the time of diagnosis and after 2 (t1), 
4 (t2), 8 (t3), 12 weeks (t4), 4–7 months (t5), and 8–12 
(t6) months of trilostane treatment. At t1-t3, t5 and t6 
the test was performed 2–3 h after the daily dose of tri-
lostane. At t4 the ACTH-stimulation test was performed 
24 hours after the last trilostane application. The treat-
ment goal at t1–t3, t5 and t6 was a serum cortisol con-
centration between 1.5 and 5 ug/dl after ACTH-stimu-
lation (Burkhardt et al., 2013). In dogs with post-ACTH 
cortisol concentration lower or higher than the target 
range, the trilostane dose was reduced or increased, re-
spectively. The dose adjustments were made in incre-
ments of 2.5–10 mg/dog/day depending on the dog’s 
size. The treatment goal at t4 was a post-ACTH cortisol 
concentration ≤ 10 ug/dl. In dogs with a post-ACTH 
cortisol concentration > 10 ug/dl and in which the own-
er complained of polydipsia, polyuria, panting or rest-
lessness in the late afternoon or at night, the treatment 
was changed to twice daily therapy (dividing the daily 
trilostane dose to q12h). Control of cortisol release was 
classified according to the post-ACTH cortisol concen-
trations as: excessive (< 1.5 ug/dl), adequate (1.5–5 ug/dl) 
or inadequate (> 5 ug/dl).
Statistical analysis
Variables were tested for normality by use of the 
Shapiro-Wilk test and analyzed by means of non-para-
metric statistical methods (GraphPad Prism6, GraphPad 
Software, San Diego, CA, USA; SPSS 22.0 for Windows; 
SPSS Inc, Chicago, IL, USA). At the time point of 
diagnosis the scores of each clinical sign and the total 
clinical score were correlated with baseline cortisol, 
post-ACTH cortisol, cACTH, baseline/4h/8h cortisol 
values of the LDDS test, thrombocyte count, serum 
alkaline phosphatase (ALP) and serum lipase concentra-
tions. During reevaluations the scores of each clinical 
sign and the total clinical score were compared with 
baseline cortisol, post-ACTH cortisol and cACTH con-
centrations. Ranges and median values are reported. 
Linear correlations between clinical scores and labora-
tory values were calculated by Spearman rank non-pa-
rametric correlation. Weighted kappa was calculated to 
assess the agreement between categorization according 
to the clinical score and post-ACTH cortisol. Differenc-
es between groups were tested by the Kruskal-Wallis test 
and Dunn’s post test. Differences were considered sig-
nificant at values of p < 0.05.
Results
Comparing clinical signs and laboratory 
parameters 
Time of diagnosis
Eighteen owner questionnaires were filled out at the time 
of diagnosing HAC. There was no significant correlation 
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Reevaluations
Ninety-seven owner questionnaires were filled out dur-
ing reevaluations. The median number of owner ques-
tionnaires filled out per dog was 3 (1–7). There was no 
significant correlation of the total clinical score with the 
cortisol values of the ACTH-stimulation test or the 
cACTH (Fig. 2). The following significant, but weak 
correlations between laboratory parameters and clinical 
scores were found: baseline cortisol and abdominal girth 
(r=0.3, p=0.01, n=88), post-ACTH cortisol and appe-
tite (r=0.2, p=0.04, n=97), post-ACTH cortisol and 
body weight increase (r=0.2, p=0.03, n=94). Grouping 
dogs according to their control of cortisol release (ex-
cessive, adequate, inadequate), revealed no significant 
difference in the scores of the clinical signs between the 
3 groups (Fig. 3). The weighted kappa for post-ACTH 
cortisol compared to the total clinical score categories 
was 0.058 (poor agreement).
Dosing of trilostane 
In 24 dogs a follow-up of more than 3 months was avail-
able. In 12 of them (50%) the trilostane treatment reg-
imen was changed from once to twice daily during the 
evaluation period. The reason for the change was a 
worsening of the clinical signs (polydipsia, polyuria, 
panting and restlessness) in the late afternoon or at night 
and/or a post-ACTH cortisol concentration > 10 ug/dl 
24h after the last trilostane dose. At the time of the 
treatment change the total daily trilostane dose was di-
vided, and in selected cases slightly increased by about 
5%. In the twice-daily treated group, all except one of 
the dogs had a positive ACTH-stimulation test at the 
time point of diagnosis, whereas in the once-daily treat-
ed group, only 6 had a positive ACTH-stimulation test. 
This difference was not significant (p=0.07) (Fig. 4).
Discussion
In the present study we were able to show for the first 
time that, at the time point of diagnosis, owner-report-
ed clinical signs of dogs with HAC correlated neither 
with cortisol concentrations of the tests to confirm the 
diagnosis nor with the cACTH concentration. This find-
ing was fairly surprising, as one would expect that cases 
with only mild clinical signs would have a lower degree 
of cortisol hypersecretion and a less decreased hypotha-
lamic-pituitary-adrenal axis sensitivity than cases with 
more severe clinical signs (Behrend et al., 2013). On the 
one hand, the lack of correlation could be due to the 
subjectivity of the owner questionnaires. On the other 
hand, individual sensitivity to cortisol could play a role, 
meaning that some dogs show moderate to severe signs 
even though their cortisol hypersecretion is only mild. 
This phenomenon has been described in human medi-
cine and, although not yet documented in veterinary 
Figure 1: Correlation of the total clinical score with the baseline cortisol concentration (A), 
the post-ACTH cortisol concentration (B), the cACTH concentration (C) and the 8h cortisol 
oncentration during the low-dose dexamethasone suppression (LDDST) (D) at the time of 
diagnosing HAC in 18 dogs. 
Figure 2: Correlation of the total clinical score with the baseline cortisol concentration (A), 
the post-ACTH cortisol concentration (B) and the cACTH concentration (C) at 97 re-evalua-
tions during trilostane therapy in 32 dogs.
between any of the cortisol values (baseline or post-
ACTH cortisol, 0/4/8h LDDST cortisol value) or the 
cACTH concentration with the score for any clinical 
parameter or with the total clinical score (Fig. 1). Com-
paring scores for the clinical signs of dogs with a positive 
ACTH-stimulation test with those with a negative test 
result did not reveal any significant differences. 
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medicine, could also exist in dogs (Nieman et al., 2008; 
Zografos et al., 2014). It is also possible that not only 
cortisol concentrations contribute to clinical signs, but 
also cortisol precursor concentrations and that therefore 
correlation of clinical signs with a cortisol-based mon-
itoring method is less favourable (Behrend et al., 2005). 
Another aim of the study was to evaluate the agreement 
between clinical signs reported by owners and cortisol 
and cACTH concentrations during trilostane therapy. 
Some owners were highly satisfied and documented 
substantial improvement, although the post-ACTH cor-
tisol levels were still fairly increased and accordingly, 
there was no significant correlation between the total 
clinical score and the cortisol concentrations (basal, 
post-ACTH). This observation is in agreement with a 
study by Wehner and coworkers (2013) who were also 
not able to show a significant correlation between the 
absolute clinical score and the baseline or post-ACTH 
cortisol concentration in their trilostane-treated dogs. 
In the study by Ramsey et al. (2015) the correlation 
between clinical signs and ACTH-test results was weak 
but still significant. This discrepancy is difficult to ex-
plain, but the higher case number in the latter study or 
differences within the owner questionnaires could ac-
count for the different results. Several other explana-
tions for the lack of correlation between clinical signs 
and cortisol values in our and in the study of Wehner 
and coworkers have to be considered. As noted above, 
this could be due to the subjectivity inherent in the 
owner questionnaires. Further, in our study, owners were 
not aware of their answers to the previous question-
naires, which could, however, have helped them to assess 
the improvement of clinical signs between the first and 
further rechecks. On the other hand, clinical signs 
might not only be related to the extent but also to the 
duration of cortisol excess, a phenomenon which has 
been documented in human medicine (Nieman, 2015). 
Finally, timing of the ACTH-stimulation test in relation 
to trilostane administration has an influence on the 
magnitude of the cortisol concentration and stimula-
tion, which in turn could lead to a lack of correlation 
between clinical signs and cortisol concentrations. This 
explanation, however, can be excluded in this study, as 
the test protocol was standardized and the ACTH-stim-
ulation always performed 2–3 h after the daily dose of 
trilostane.
Classifying the dogs of this study into excessively-, ad-
equately- or inadequately-controlled groups according 
to their cortisol release during the ACTH-stimulation 
test revealed no difference in their total clinical score. 
The weighted kappa even defined the agreement be-
tween post-ACTH cortisol and the total clinical score 
as poor. This was surprising and incongruent with our 
clinical experience. Although the ACTH-stimulation 
test certainly can be discussed as a gold standard in 
Figure 3: The total clinical score from 97 re-evaluations during trilostane therapy 
in 32 dogs. Control of cortisol release is classified according to the post-ACTH 
cortisol concentrations as: excessive (< 1.5 ug/dl), adequate (1.5–5 ug/dl) or inade-
quate (> 5 ug/dl).
Figure 4: Number of dogs with a positive (post-ACTH cortisol ≥ 17 ug/dl) or negative (post-
ACTH cortisol < 17 ug/dl) ACTH-stimulation test at the time of diagnosis in relation to their 
trilostane treatment frequency (once versus twice daily).
monitoring trilostane therapy, it has been proven to 
objectively assess the therapeutic response. Treatment 
monitoring with the use of the ACTH-stimulation test 
is very often successful and helpful in identifying exces-
sively-controlled dogs (Sieber-Ruckstuhl et al., 2006; 
Galac et al., 2009; Burkhardt et al., 2013). Again, the 
problem could be the subjectivity of owner question-
naires, which may even increase when owners are not 
able to look back at their answers on previous question-
naires. In addition, the owners’ perception of clinical 
signs may not reflect the clinical status assessed by the 
veterinarian in charge. The agreement of the clinical 
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score with the cortisol concentrations might possibly be 
improved if the clinical assessment of a veterinarian 
were to be included in the score. However, to increase 
the reliability of the clinical score in this way, the same 
veterinarian would have to judge each patient at each 
recheck, which is hardly possible in a large clinical in-
stitution. 
Trilostane does not normalize cortisol concentrations 
in dogs with HAC for a period of 24 hours (Lehnert et 
al., 2007). It has been suggested that using trilostane 
twice daily might increase the number of dogs with a 
good clinical response compared to only once-daily 
therapy (Arenas et al., 2013). In the present study, the 
treatment regimen had been changed from once to twice 
daily in 12 of 24 dogs during the evaluation period. 
Reasons for the change were worsening of the clinical 
signs late in the afternoon or at night and/or increased 
post-ACTH cortisol concentrations 24h after the last 
trilostane dose. This number is much higher than in 
earlier years. We believe that the main reason for this is 
the substantially lower trilostane starting dose used now-
adays (1–2 mg/kg compared to > 4 mg/kg). However, for 
this study we can assess neither which treatment regimen 
is more favourable nor whether the twice-daily treat-
ment would lead to a better correlation between the 
cortisol values and the total clinical score. Interestingly, 
all except one dog in which the trilostane treatment 
frequency was changed from once- to twice- daily ther-
apy had a positive ACTH-stimulation test at the time 
point of diagnosis. In contrast, for dogs controlled with 
the once-daily trilostane treatment, the same number 
had a positive as a negative ACTH-stimulation test. A 
positive ACTH-stimulation test reflects an increased 
capacity to synthesize and secrete excessive amounts of 
cortisol. Therefore, one could argue that dogs with a 
positive ACTH-stimulation test, reflecting a greater ca-
pacity to synthesize cortisol, would need more frequent 
trilostane application to control the disease. This inter-
esting finding should be further addressed in future 
studies. 
A limitation of this and also other trilostane studies is 
the lack of a gold standard with which to classify dogs 
as excessively-, adequately- or inadequately-controlled. 
This is reflected in the discrepant results between the 
studies, due to the fact that there are different monitor-
ing standards: clinical signs and cortisol values. All 
studies, including ours, reflect however that neither 
cortisol nor clinical parameters should be judged sepa-
rately. Of interest are the results of a very recent study 
(Ramsey et al., 2015) comparing 4 different corti-
sol-based monitoring methods with the clinical score. 
Two cortisol-based monitoring methods (one using the 
pre-trilostane cortisol value and the other the pre-trilos-
tane in combination with the 3 hours post-trilostane 
cortisol) seemed to reflect clinical control better than 
results of the ACTH-stimulation test (Ramsey et al., 
2015). Future studies should therefore include such cor-
tisol-based monitoring methods, possibly in combina-
tion with an optimized clinical evaluation sheet. 
In summary, comparing the score of the clinical signs 
reported by owners with the results of the ACTH-stim-
ulation test 2-3 hours after trilostane application re-
vealed no significant correlation of the cortisol values 
with the clinical signs. Therefore we conclude that mon-
itoring of trilostane therapy based on clinical signs as-
sessed by owners is only partially helpful in differenti-
ating excessively-, adequately- or inadequately-controlled 
dogs. Neither under- nor overdosing could be identified 
based on the clinical score. If trilostane is used in a low-
dose (1–2 mg/kg), treatment frequency often has to be 
changed from once to twice daily.
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Absence de corrélation entre les 
symptômes cliniques et les valeurs 
de laboratoire chez les chiens souf-
frant d’hyperadrénocorticisme avant 
et durant un traitement au trilostane 
Le traitement au trilostane, médicament de choix dans 
les cas d‘hyperadrénocorticisme hypophyso-dépendant 
chez le chien, est évalué sur la base de la disparition des 
symptômes cliniques et des résultats des tests de stimu-
lation à l’ACTH. Le but de la présente étude prospective 
était de comparer les symptômes cliniques (évalués par 
les propriétaires) avec les concentrations de cortisol et 
d’ACTH endogène avant et durant un traitement au 
trilostane (dose initiale 1–2 mg/kg, 1× par jour). On a 
utilisé un questionnaire composé de 9 questions rela-
tives aux symptômes cliniques sur la base desquels on a 
calculé un score clinique total. Dix-huit questionnaires 
ont été remplis au moment du diagnostic et 97 durant 
le traitement par les propriétaires de 32 chiens. Un test 
de stimulation à l’ACTH a été réalisé lors de chaque 
contrôle. Il existait de faibles corrélations entre le péri-
mètre abdominal, l’appétit et la prise de poids et les taux 
de cortisol durant le traitement. Le score clinique total 
n’était toutefois pas corrélé avec les concentrations de 
cortisol ou d’ACTH. Chez la moitié des chiens, la dose 
de trilostane a du être répartie en deux prises journa-
lières. Les symptômes cliniques jugés par les proprié-
taires montraient une mauvaise corrélation avec les taux 
de cortisol et d’ACTH durant le traitement au trilostane. 
Si on dose ce médicament de façon faible, il y a souvent 
lieu d’augmenter la fréquence des prises. 
Assenza di relazione tra i sintomi  
clinici e i valori di laboratorio nei  
cani affetti da iperadrenocorticismo 
prima e durante il trattamento con 
trilostano
Il trattamento con trilostano, il farmaco di prima scelta 
per il trattamento dell’iperadrenocorticismo ipofisario 
(PDH) nel cane, è stato valutato via la scomparsa di 
sintomi clinici e via il risultato del test di stimolazione 
ACTH. L’obiettivo di questo studio prospettivo era di 
studiare la conformità dei sintomi clinici (valutati dal 
proprietario), via la somministrazione di cortisolo e di 
concentrazioni di ACTH endogeno, prima e durante la 
terapia con trilostano (dose iniziale 1–2 mg/kg, 1× al 
giorno). È stato utilizzato un questionario con 9 doman-
de sullo stato clinico del PDH ed è stato calcolato un 
punteggio totale dello stato clinico come risultato. Sono 
stati completati dai proprietari di 32 cani diciotto que-
stionari al momento della diagnosi e 97 durante la tera-
pia. Un test di stimulazione con ACTH è stato eseguito 
ad ogni controllo. Durante la terapia, si sono rilevate 
poche correlazioni con i valori di cortisolo per quel che 
riguarda la circonferenza del ventre, l’appetito e l’au-
mento di peso. Tuttavia, il punteggio totale dello stato 
clinico non era correlato alle concentrazioni di ACGT 
e di cortisolo. Durante lo studio, nel 50% dei cani la 
dose di trilostano è stata modificata da una a due dosi 
giornaliere.  I sintomi clinici valutati dai proprietari 
hanno evidenziato una scarsa corrispondenza tra le con-
centrazioni di cortisolo e ACTH durante la terapia con 
trilostano. Se il trilostano viene somministrato a basso 
dosaggio, spesso la frequenza deve essere aumentata. 
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